◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › D › DYN

Dyne Therapeutics Inc (DYN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-08-22

Dyne Therapeutics Inc (DYN) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 289 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, DYN reported $0M in revenue and ($446M) in net income.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Interactive charts & full statements →

DYN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$506M	$1.4B	$842M	$1.5B	$3M	$3M	$1.6B	$2.3B	$2.5B	$3.5B	$3.1B
Gross Profit	—	($2M)	($2M)	($2M)	($3M)	($1M)	($1M)	$0M	$0M	($2.4B)	($915M)	($1.2B)	$321M	($1.1B)	($265M)	$622M	$1.1B	$1.3B	$1.7B	$1.1B
Gross Margin %	—	—	—	—	—	—	—	—	—	-479.5%	-67.0%	-140.9%	21.9%	-38066.7%	-8833.3%	39.2%	49.2%	51.6%	47.8%	35.1%
Operating Income (EBIT)	($537M)	($468M)	($344M)	($242M)	($171M)	($150M)	($59M)	($14M)	($5M)	($412M)	($640M)	$64M	($318M)	($318M)	$714M	($236M)	($11M)	($834M)	$709M	$605M
Operating Margin %	—	—	—	—	—	—	—	—	—	-81.4%	-46.9%	7.6%	-21.7%	-10600.0%	23800.0%	-14.9%	-0.5%	-33.8%	20.0%	19.5%
Net Income	($519M)	($446M)	($317M)	($236M)	($165M)	($149M)	($59M)	($14M)	($5M)	$76M	($1.2B)	$50M	($67M)	($356M)	$87M	($1.6B)	($234M)	($1.3B)	$174M	$264M
Net Margin %	—	—	—	—	—	—	—	—	—	15.0%	-90.8%	5.9%	-4.6%	-11866.7%	2900.0%	-103.8%	-10.1%	-51.1%	4.9%	8.5%
EBITDA	($495M)	($438M)	($315M)	($233M)	($169M)	($148M)	($58M)	($15M)	($5M)	$949M	$106M	$736M	$292M	$150M	$113M	($1.6B)	$734M	($173M)	$902M	$830M
Earnings Per Share (EPS)	$-3.44	$-3.47	$-3.37	$-3.95	$-3.18	$-2.93	$-1.24	$-0.30	$-0.03	$0.47	$-9.61	$0.40	$-0.53	$-3.56	$0.87	$-13.48	$-1.93	$-1.25	$0.20	$0.25
Shares Outstanding (M)	165M	128M	94M	60M	52M	51M	47M	45M	—	162M	129M	126M	126M	100M	100M	122M	121M	1,010M	870M	1,042M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DYN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$2M	$0M
Gross Profit	—	($1M)	($1M)	—	$0M	($1M)	$1M	$0M
Gross Margin %	—	—	—	—	—	—	50.0%	—
Operating Income (EBIT)	($182M)	($125M)	($116M)	($114M)	($116M)	($122M)	($97M)	($106M)
Operating Margin %	—	—	—	—	—	—	-6177.3%	—
Net Income	($179M)	($121M)	($112M)	($108M)	($111M)	($115M)	($90M)	($97M)
Net Margin %	—	—	—	—	—	—	-5696.1%	—
EBITDA	($173M)	($116M)	($101M)	($105M)	($110M)	($115M)	($89M)	($97M)
Earnings Per Share (EPS)	$-1.08	$-0.73	$-0.87	$-0.76	$-0.97	$-1.05	$-0.88	$-0.96
Shares Outstanding (M)	165M	165M	128M	142M	114M	110M	102M	101M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DYN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Cash from Operations (CFO)	($478M)	($403M)	($292M)	($188M)	($154M)	($120M)	($47M)	($12M)	($4M)	$585M	$676M	$94M	($62M)	$175M	($44M)	($20M)	$423M	$135M	$319M	$341M
Capital Expenditures (CapEx)	$21M	$2M	$2M	$1M	$3M	$4M	$1M	$2M	$0M	$224M	$326M	$275M	$0M	$98M	$0M	$242M	$333M	$0M	$0M	$0M
Free Cash Flow (FCF)	($499M)	($405M)	($295M)	($189M)	($157M)	($123M)	($48M)	($13M)	($4M)	$361M	$350M	($181M)	($62M)	$77M	($44M)	($262M)	$90M	$135M	$319M	$341M
FCF Margin %	—	—	—	—	—	—	—	—	—	71.3%	25.6%	-21.5%	-4.2%	2566.7%	-1466.7%	-16.5%	3.9%	5.5%	9.0%	11.0%
Dividends Paid	—	—	—	—	—	—	—	—	—	$22M	$22M	$23M	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DYN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($130M)	($145M)	($112M)	($91M)	($95M)	($106M)	($84M)	($75M)
Capital Expenditures (CapEx)	$2M	$0M	$0M	$19M	$0M	$1M	$1M	$0M
Free Cash Flow (FCF)	($132M)	($145M)	($112M)	($110M)	($95M)	($107M)	($85M)	($75M)
FCF Margin %	—	—	—	—	—	—	-5433.2%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DYN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31
Total Assets	$994M	$1.2B	$691M	$165M	$306M	$426M	$353M	$16M	$8M	$11.8B	$13.1B	$11.5B	$11.2B	$5.3B	$4.5B	$4.1B	$10.0B	$11.0B	$14.2B	$13.2B
Cash & Cash Equivalents	$676M	$893M	$435M	$122M	$172M	$201M	$301M	$15M	$8M	$365M	$1.8B	$505M	$1.9B	$843M	$348M	$396M	$291M	$471M	$693M	$328M
Total Liabilities	$292M	$215M	$61M	$74M	$54M	$57M	$11M	$2M	$13M	$9.9B	$11.0B	$8.6B	$8.2B	$3.1B	$2.0B	$3.0B	$7.3B	$8.0B	$9.7B	$8.7B
Total Debt (Short + Long-Term)	$205M	$154M	$5M	$5M	$5M	$4M	$0M	$0M	$0M	$105M	$201M	$83M	$31M	$13M	$29M	$4M	$148M	$807M	$64M	$51M
Total Shareholders' Equity	$702M	$972M	$630M	$91M	$252M	$368M	$342M	$14M	($5M)	$1.9B	$2.0B	$2.9B	$3.0B	$2.2B	$2.5B	$1.1B	$2.7B	$2.9B	$4.5B	$4.5B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive DYN viewer.

Other Companies in BIOTECHNOLOGY

TARS · Tarsus Pharmaceuticals Inc — $4 billion
ELVN · Enliven Therapeutics Inc. — $4 billion
LEGN · Legend Biotech Corp — $3 billion
VKTX · Viking Therapeutics Inc — $3 billion
ARQT · Arcutis Biotherapeutics Inc — $3 billion
RCUS · Arcus Biosciences Inc — $3 billion
DNLI · Denali Therapeutics Inc — $3 billion
QURE · Uniqure NV — $3 billion

← DYLG All “D” companies DYNAMATECH →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.